Oscar Health CEO's $11.9M Bet Pays Off After Q1 Surge

NEW YORK, May 19 —

Oscar Health CEO Mark Bertolini spent $11.92 million buying company stock at $11.92 a share in early April, a trade that looked either visionary or reckless at the time. Then Q1 earnings landed, news outlets called it record quarterly income, the stock hit a 5-year high, and Trefis reported a 32% surge across five trading days. With shares now at $25.30, more than double Bertolini's entry price and roughly 25% above Wall Street's consensus target, the CEO's bet has definitively paid off. His CFO, meanwhile, has started selling.

The Conviction Trade

Bertolini's April 6 purchase has two parts. Three days earlier, on April 3, he exercised options covering 5,733,334 shares. On April 6, SEC filings show a tax-withholding disposition of 1,000,001 shares at $11.92 — a routine administrative event when options vest and the tax bill comes due. What is not routine is what came next. On the same day, Bertolini went back to the open market and bought 1,000,000 shares at $11.92, committing $11.92 million of personal capital. He effectively replaced the shares he was forced to surrender for taxes, in cash, voluntarily. That is a specific insider signal: not the passive exercise of compensation already granted, but a decision to put fresh money at risk at precisely the moment his tax bill arrived.

The Quarter That Delivered

Bertolini's timing proved well-placed. Oscar filed its Q1 2026 results in an 8-K on May 6. News coverage called the quarter record quarterly income, with Simply Wall St noting guidance reaffirmation alongside the strong results. Yahoo Finance cited CMS updates as a contributing factor to the stock move that followed, which notched a 5-year high. The underlying business supports the enthusiasm: trailing twelve-month revenue stands at $13.30 billion, with 52.6% year-over-year growth. For a health insurer that spent years absorbing the cost of building its technology platform and membership base, that revenue pace shows the model is working.

Now the CFO Is Selling

Three weeks after the earnings release, Oscar CFO Richard Scott Blackley sold 100,000 shares on May 14: 91,259 at $23.10 and 8,741 at $23.79, totaling approximately $2.32 million, per SEC filings. Insider selling after a big run is not inherently alarming. Executives have personal financial needs and diversification mandates. But the optics here are specific. The CEO was a buyer at $11.92; the CFO became a seller in the $23s. Two top executives of the same company are running in opposite directions, and the one heading for the exit is locking in gains at a near-historic high for the stock.

Above the Tape

At $25.30, OSCR trades roughly 25% above the analyst consensus price target of $20.30. That premium does not mean the bull case is wrong. Consensus targets lag behind fast-moving stories routinely. And 52.6% revenue growth at $13.3 billion in trailing revenue is not a small-company optical illusion. GuruFocus raised overvaluation concerns directly after an 8.5% rally in the shares. The tension is straightforward: revenue scale is real, but Oscar has long been a growth-first, profit-later story. The stock now reflects a profit outcome that formal analyst estimates have not yet endorsed. The next earnings print needs to show that the Q1 record was a trajectory, not a one-quarter event.

What Changes the Math

The next signal worth tracking is whether analyst price targets migrate upward following Q1 and guidance reaffirmation. If analysts revise toward current prices, the premium compresses and the valuation case firms. If targets hold near $20, the stock is priced for a step-change in profitability that has not yet appeared in official models. The CFO sale will also draw scrutiny: a single transaction is noise, but continued selling into strength would shift the insider picture. Bertolini's original conviction has been validated by events. Whether the stock was merely early and is now fully priced, or whether there is a second act to this story, depends on what the next quarter's numbers show. For a full fundamental breakdown, run the free Oscar Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

What happened to Oscar Health stock after Q1 2026 earnings?

Oscar Health filed Q1 2026 results in an 8-K on May 6, with news outlets characterizing the quarter as record quarterly income and guidance reaffirmed. The stock hit a 5-year high, and Trefis reported a 32% surge across five trading days, with CMS updates cited as a contributing factor to the move.

Did Oscar Health's CEO buy stock recently?

ase came on the same day he recorded a tax-withholding disposition from an option exercise, making the open-market buy a deliberate decision to add exposure rather than a routine compensation event.

Is Oscar Health stock overvalued now?

At $25.30, OSCR trades roughly 25% above the analyst consensus price target of $20.30. GuruFocus raised overvaluation concerns after an 8.5% rally in the shares. The 52.6% revenue growth supports the bull case, but the stock has moved well ahead of formal analyst estimates.

Why is Oscar Health's CFO selling shares?

CFO Richard Scott Blackley sold 100,000 shares on May 14, 2026, at prices between $23.10 and $23.79, totaling approximately $2.32 million, per SEC filings. Executives sell for many reasons including personal financial planning and diversification, but the timing creates a notable divergence: the CEO bought at $11.92 and the CFO is selling in the $23s.

What is Oscar Health's revenue growth rate?

Oscar Health's trailing twelve-month revenue stands at $13.30 billion, reflecting 52.6% year-over-year growth. This top-line expansion is central to the investment case. The question is whether that growth is converting into durable profitability — the Q1 2026 results, described as record quarterly income, point in that direction.